Acadia Pharma (ACAD) Misses Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $20.57 --0%
Revenue Growth %: +19.3%
Financial Fact:
Net loss: -71.61M
Today's EPS Names:
ATS, SICP, FTCO, More
Revenue Growth %: +19.3%
Financial Fact:
Net loss: -71.61M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q4 EPS of $0.28, $0.01 worse than the analyst estimate of $0.29. Revenue for the quarter came in at $231 million versus the consensus estimate of $223.77 million.
Full Year 2024 Financial Guidance
- DAYBUE net product sales in the range of $370 to $420 million.
- NUPLAZID net product sales in the range of $560 to $590 million.
- GAAP R&D expense in the range of $305 to $325 million.
- GAAP SG&A expense in the range of $455 to $480 million.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McDonald’s posts better-than-expected third-quarter comparable sales
- L.B. Foster (FSTR) Reports In-Line Q3 EPS ; Offers Guidance
- CS Disco, Inc (LAW) Misses Q3 EPS by 6c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
